Cardax Inc Stock Performance
| CDXI Stock | USD 0.0001 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Cardax are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Cardax Inc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Cardax is not utilizing all of its potentials. The newest stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Begin Period Cash Flow | 19.3 K | |
| Total Cashflows From Investing Activities | -14.6 K |
Cardax |
Cardax Relative Risk vs. Return Landscape
If you would invest 0.01 in Cardax Inc on April 25, 2025 and sell it today you would earn a total of 0.00 from holding Cardax Inc or generate 0.0% return on investment over 90 days. Cardax Inc is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Cardax, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cardax Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cardax's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Cardax Inc, and traders can use it to determine the average amount a Cardax's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| CDXI |
Based on monthly moving average Cardax is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cardax by adding Cardax to a well-diversified portfolio.
Cardax Fundamentals Growth
Cardax Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Cardax, and Cardax fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cardax Pink Sheet performance.
| Return On Asset | -1.13 | |||
| Operating Margin | (5.85) % | |||
| Current Valuation | 5.34 M | |||
| Shares Outstanding | 802.52 K | |||
| Price To Earning | (22.00) X | |||
| Price To Sales | 0.0008 X | |||
| Revenue | 538.95 K | |||
| EBITDA | (2.64 M) | |||
| Cash And Equivalents | 61.71 K | |||
| Cash Per Share | 0.08 X | |||
| Total Debt | 1000 K | |||
| Debt To Equity | (1.23) % | |||
| Book Value Per Share | (14.15) X | |||
| Cash Flow From Operations | (1.79 M) | |||
| Earnings Per Share | (7.08) X | |||
| Total Asset | 1.43 M | |||
| Retained Earnings | (72.33 M) | |||
| Current Asset | 413.66 K | |||
| Current Liabilities | 4.6 M | |||
About Cardax Performance
By evaluating Cardax's fundamental ratios, stakeholders can gain valuable insights into Cardax's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cardax has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cardax has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.Things to note about Cardax Inc performance evaluation
Checking the ongoing alerts about Cardax for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Cardax Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cardax Inc generated a negative expected return over the last 90 days | |
| Cardax Inc has some characteristics of a very speculative penny stock | |
| Cardax Inc has a very high chance of going through financial distress in the upcoming years | |
| Cardax Inc currently holds 1000 K in liabilities. Cardax Inc has a current ratio of 0.09, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cardax until it has trouble settling it off, either with new capital or with free cash flow. So, Cardax's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cardax Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cardax to invest in growth at high rates of return. When we think about Cardax's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 538.95 K. Net Loss for the year was (5.06 M) with profit before overhead, payroll, taxes, and interest of 342.82 K. | |
| Cardax Inc currently holds about 61.71 K in cash with (1.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Cardax's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cardax's stock is overvalued or undervalued compared to its peers.
- Examining Cardax's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cardax's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cardax's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cardax's pink sheet. These opinions can provide insight into Cardax's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cardax Pink Sheet analysis
When running Cardax's price analysis, check to measure Cardax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardax is operating at the current time. Most of Cardax's value examination focuses on studying past and present price action to predict the probability of Cardax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardax's price. Additionally, you may evaluate how the addition of Cardax to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |